Compare Crispr Therapeutics AG (CRSP) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kyndryl Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $50.95 (market cap $5.06B), while Kyndryl Holdings Inc trades at $11.86 (market cap $2.49B). The key difference: Crispr Therapeutics AG is far larger — about 2× Kyndryl Holdings Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Kyndryl Holdings Inc for 36 Days on average.
| CRSP | KD | |
|---|---|---|
Market Cap | $5.06B | $2.49B |
Volume | 1,678,371 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $74.92 | $29.76 |
52-Week Low | $44.34 | $10.59 |
Typical Hold Time | 77 Days | 36 Days |
Enterprise Value | $3.48B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
Kyndryl Holdings (KD) trades at $11.45, down 0.26% on the day, with technical indicators showing bearish momentum. The company reported mixed quarterly results, missing Q4 2025 and Q1 2026 EPS estimates but beating in Q2 2026. Recent financials show improved profitability with 2025 net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B in 2025. Analyst sentiment is cautious with a consensus 'Hold' rating and $14.67 price target, while institutional activity includes recent purchases by Virginia Retirement Systems.
KD presents a turnaround story with improving profitability but faces revenue headwinds and competitive pressures. The stock trades at reasonable valuation multiples (P/E 30.95, P/S 0.18) with positive cash flow generation. Key risks include ongoing revenue declines and high debt levels, while opportunities exist in AI initiatives and government contracts. The current technical weakness may present entry points for patient investors betting on management's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
